➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
McKesson
Moodys
Dow
AstraZeneca

Last Updated: August 13, 2020

DrugPatentWatch Database Preview

LEVETIRACETAM IN SODIUM CHLORIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Levetiracetam In Sodium Chloride patents expire, and what generic alternatives are available?

Levetiracetam In Sodium Chloride is a drug marketed by Aurobindo Pharma Ltd, Gland Pharma Ltd, and Hq Speciality Pharma. and is included in three NDAs.

The generic ingredient in LEVETIRACETAM IN SODIUM CHLORIDE is levetiracetam. There are thirty-five drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

US ANDA Litigation and Generic Entry Outlook for Levetiracetam In Sodium Chloride

A generic version of LEVETIRACETAM IN SODIUM CHLORIDE was approved as levetiracetam by MYLAN on November 4th, 2008.

  Start Trial

Drug patent expirations by year for LEVETIRACETAM IN SODIUM CHLORIDE
Recent Clinical Trials for LEVETIRACETAM IN SODIUM CHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NYU Langone HealthPhase 2
Walter Reed National Military Medical CenterPhase 2
Lady Hardinge Medical CollegePhase 2/Phase 3

See all LEVETIRACETAM IN SODIUM CHLORIDE clinical trials

Pharmacology for LEVETIRACETAM IN SODIUM CHLORIDE

US Patents and Regulatory Information for LEVETIRACETAM IN SODIUM CHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd LEVETIRACETAM IN SODIUM CHLORIDE levetiracetam INJECTABLE;INTRAVENOUS 207160-001 Jan 4, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
Hq Speciality Pharma LEVETIRACETAM IN SODIUM CHLORIDE levetiracetam INJECTABLE;INTRAVENOUS 202543-001 Nov 9, 2011 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Gland Pharma Ltd LEVETIRACETAM IN SODIUM CHLORIDE levetiracetam INJECTABLE;INTRAVENOUS 206880-001 Oct 25, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
Hq Speciality Pharma LEVETIRACETAM IN SODIUM CHLORIDE levetiracetam INJECTABLE;INTRAVENOUS 202543-002 Nov 9, 2011 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Aurobindo Pharma Ltd LEVETIRACETAM IN SODIUM CHLORIDE levetiracetam INJECTABLE;INTRAVENOUS 207160-002 Jan 4, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Mallinckrodt
McKinsey
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.